AAPL315.91-4.06 (-1.27%) ▼|ABBV250.62-5.84 (-2.28%) ▼|ABT105.97-2.37 (-2.18%) ▼|ACN177.76-8.96 (-4.80%) ▼|ADBE257.30-9.22 (-3.46%) ▼|AMAT470.11+15.40 (+3.39%) ▲|AMD510.97+33.40 (+6.99%) ▲|AMGN397.35-39.88 (-9.12%) ▼|AMT177.08+1.23 (+0.70%) ▲|AMZN257.01-1.50 (-0.58%) ▼|AVGO367.18+9.29 (+2.59%) ▲|AXP326.95+0.79 (+0.24%) ▲|BA211.52-0.73 (-0.34%) ▼|BAC62.70+0.02 (+0.02%) ▲|BKNG180.60-12.69 (-6.57%) ▼|BLK1,104.39-12.18 (-1.09%) ▼|BMY65.06-1.76 (-2.63%) ▼|BNY164.00-0.84 (-0.51%) ▼|BRK-B504.46-1.58 (-0.31%) ▼|C137.58-0.15 (-0.11%) ▼|CAT826.91+12.97 (+1.59%) ▲|CL88.60-0.17 (-0.19%) ▼|CMCSA26.08-0.41 (-1.55%) ▼|COF215.20-4.40 (-2.00%) ▼|COP134.37+0.11 (+0.08%) ▲|COST909.62-6.13 (-0.67%) ▼|CRM248.81-10.43 (-4.02%) ▼|CSCO109.08-0.12 (-0.11%) ▼|CVS96.49-0.25 (-0.26%) ▼|CVX209.56+0.96 (+0.46%) ▲|DE683.49-10.05 (-1.45%) ▼|DHR206.03-1.63 (-0.78%) ▼|DIS104.56-0.76 (-0.72%) ▼|DUK121.26+1.04 (+0.86%) ▲|EMR152.12-0.70 (-0.46%) ▼|FDX316.67-5.85 (-1.81%) ▼|GD356.85-2.54 (-0.71%) ▼|GE337.88+0.76 (+0.23%) ▲|GEV970.68+28.73 (+3.05%) ▲|GILD146.62-4.38 (-2.90%) ▼|GM86.01-1.76 (-2.00%) ▼|GOOG336.36+1.05 (+0.31%) ▲|GOOGL339.57+1.11 (+0.33%) ▲|GS1,036.86-1.75 (-0.17%) ▼|HD315.43-5.63 (-1.75%) ▼|HON208.35-1.27 (-0.60%) ▼|IBM232.28-2.62 (-1.11%) ▼|INTC105.74+9.94 (+10.38%) ▲|INTU313.48-19.22 (-5.78%) ▼|ISRG351.24-15.46 (-4.22%) ▼|JNJ269.14-6.09 (-2.21%) ▼|JPM355.16-3.49 (-0.97%) ▼|KO88.36+0.29 (+0.32%) ▲|LIN468.57-9.00 (-1.88%) ▼|LLY1,126.65-22.71 (-1.98%) ▼|LMT538.18+12.90 (+2.46%) ▲|LOW201.70-2.76 (-1.35%) ▼|LRCX320.04+12.39 (+4.03%) ▲|MA567.69-11.52 (-1.99%) ▼|MCD255.75+0.06 (+0.02%) ▲|MDLZ61.43+0.15 (+0.24%) ▲|MDT92.59-1.58 (-1.68%) ▼|META617.95+1.18 (+0.19%) ▲|MMM166.52-2.04 (-1.21%) ▼|MO68.04-0.84 (-1.22%) ▼|MRK148.81-1.52 (-1.01%) ▼|MS217.85+0.13 (+0.06%) ▲|MSFT492.30-7.41 (-1.48%) ▼|MU1,018.61+2.02 (+0.20%) ▲|NEE84.04+0.61 (+0.73%) ▲|NFLX76.72-1.53 (-1.96%) ▼|NKE38.17-0.23 (-0.60%) ▼|NOW133.81-7.46 (-5.28%) ▼|NVDA225.90-4.47 (-1.94%) ▼|ORCL162.52+3.74 (+2.35%) ▲|PEP138.27+0.64 (+0.47%) ▲|PFE27.94-0.52 (-1.81%) ▼|PG145.34-1.10 (-0.75%) ▼|PLTR171.94-2.39 (-1.37%) ▼|PM185.54+3.01 (+1.65%) ▲|QCOM174.78+6.04 (+3.58%) ▲|RTX199.49-1.30 (-0.65%) ▼|SBUX102.27-2.20 (-2.11%) ▼|SCHW108.52-0.78 (-0.71%) ▼|SO88.89+0.78 (+0.89%) ▲|SPG211.61+2.17 (+1.04%) ▲|T25.50-0.18 (-0.70%) ▼|TMO605.92-7.86 (-1.28%) ▼|TMUS179.68-1.84 (-1.01%) ▼|TSLA367.79+13.71 (+3.87%) ▲|TXN257.14-1.30 (-0.50%) ▼|UBER73.24-2.52 (-3.33%) ▼|UNH403.34+6.20 (+1.56%) ▲|UNP290.17+0.55 (+0.19%) ▲|UPS100.82-1.48 (-1.44%) ▼|USB62.83-0.55 (-0.86%) ▼|V368.69-6.38 (-1.70%) ▼|VZ50.13-0.02 (-0.03%) ▼|WFC88.83-1.14 (-1.27%) ▼|WMT106.07-1.08 (-1.00%) ▼|XOM159.49+0.02 (+0.01%) ▲|AAPL315.91-4.06 (-1.27%) ▼|ABBV250.62-5.84 (-2.28%) ▼|ABT105.97-2.37 (-2.18%) ▼|ACN177.76-8.96 (-4.80%) ▼|ADBE257.30-9.22 (-3.46%) ▼|AMAT470.11+15.40 (+3.39%) ▲|AMD510.97+33.40 (+6.99%) ▲|AMGN397.35-39.88 (-9.12%) ▼|AMT177.08+1.23 (+0.70%) ▲|AMZN257.01-1.50 (-0.58%) ▼|AVGO367.18+9.29 (+2.59%) ▲|AXP326.95+0.79 (+0.24%) ▲|BA211.52-0.73 (-0.34%) ▼|BAC62.70+0.02 (+0.02%) ▲|BKNG180.60-12.69 (-6.57%) ▼|BLK1,104.39-12.18 (-1.09%) ▼|BMY65.06-1.76 (-2.63%) ▼|BNY164.00-0.84 (-0.51%) ▼|BRK-B504.46-1.58 (-0.31%) ▼|C137.58-0.15 (-0.11%) ▼|CAT826.91+12.97 (+1.59%) ▲|CL88.60-0.17 (-0.19%) ▼|CMCSA26.08-0.41 (-1.55%) ▼|COF215.20-4.40 (-2.00%) ▼|COP134.37+0.11 (+0.08%) ▲|COST909.62-6.13 (-0.67%) ▼|CRM248.81-10.43 (-4.02%) ▼|CSCO109.08-0.12 (-0.11%) ▼|CVS96.49-0.25 (-0.26%) ▼|CVX209.56+0.96 (+0.46%) ▲|DE683.49-10.05 (-1.45%) ▼|DHR206.03-1.63 (-0.78%) ▼|DIS104.56-0.76 (-0.72%) ▼|DUK121.26+1.04 (+0.86%) ▲|EMR152.12-0.70 (-0.46%) ▼|FDX316.67-5.85 (-1.81%) ▼|GD356.85-2.54 (-0.71%) ▼|GE337.88+0.76 (+0.23%) ▲|GEV970.68+28.73 (+3.05%) ▲|GILD146.62-4.38 (-2.90%) ▼|GM86.01-1.76 (-2.00%) ▼|GOOG336.36+1.05 (+0.31%) ▲|GOOGL339.57+1.11 (+0.33%) ▲|GS1,036.86-1.75 (-0.17%) ▼|HD315.43-5.63 (-1.75%) ▼|HON208.35-1.27 (-0.60%) ▼|IBM232.28-2.62 (-1.11%) ▼|INTC105.74+9.94 (+10.38%) ▲|INTU313.48-19.22 (-5.78%) ▼|ISRG351.24-15.46 (-4.22%) ▼|JNJ269.14-6.09 (-2.21%) ▼|JPM355.16-3.49 (-0.97%) ▼|KO88.36+0.29 (+0.32%) ▲|LIN468.57-9.00 (-1.88%) ▼|LLY1,126.65-22.71 (-1.98%) ▼|LMT538.18+12.90 (+2.46%) ▲|LOW201.70-2.76 (-1.35%) ▼|LRCX320.04+12.39 (+4.03%) ▲|MA567.69-11.52 (-1.99%) ▼|MCD255.75+0.06 (+0.02%) ▲|MDLZ61.43+0.15 (+0.24%) ▲|MDT92.59-1.58 (-1.68%) ▼|META617.95+1.18 (+0.19%) ▲|MMM166.52-2.04 (-1.21%) ▼|MO68.04-0.84 (-1.22%) ▼|MRK148.81-1.52 (-1.01%) ▼|MS217.85+0.13 (+0.06%) ▲|MSFT492.30-7.41 (-1.48%) ▼|MU1,018.61+2.02 (+0.20%) ▲|NEE84.04+0.61 (+0.73%) ▲|NFLX76.72-1.53 (-1.96%) ▼|NKE38.17-0.23 (-0.60%) ▼|NOW133.81-7.46 (-5.28%) ▼|NVDA225.90-4.47 (-1.94%) ▼|ORCL162.52+3.74 (+2.35%) ▲|PEP138.27+0.64 (+0.47%) ▲|PFE27.94-0.52 (-1.81%) ▼|PG145.34-1.10 (-0.75%) ▼|PLTR171.94-2.39 (-1.37%) ▼|PM185.54+3.01 (+1.65%) ▲|QCOM174.78+6.04 (+3.58%) ▲|RTX199.49-1.30 (-0.65%) ▼|SBUX102.27-2.20 (-2.11%) ▼|SCHW108.52-0.78 (-0.71%) ▼|SO88.89+0.78 (+0.89%) ▲|SPG211.61+2.17 (+1.04%) ▲|T25.50-0.18 (-0.70%) ▼|TMO605.92-7.86 (-1.28%) ▼|TMUS179.68-1.84 (-1.01%) ▼|TSLA367.79+13.71 (+3.87%) ▲|TXN257.14-1.30 (-0.50%) ▼|UBER73.24-2.52 (-3.33%) ▼|UNH403.34+6.20 (+1.56%) ▲|UNP290.17+0.55 (+0.19%) ▲|UPS100.82-1.48 (-1.44%) ▼|USB62.83-0.55 (-0.86%) ▼|V368.69-6.38 (-1.70%) ▼|VZ50.13-0.02 (-0.03%) ▼|WFC88.83-1.14 (-1.27%) ▼|WMT106.07-1.08 (-1.00%) ▼|XOM159.49+0.02 (+0.01%) ▲|
27.4 C
New York
Tuesday, September 8, 2026

Tag: study

newssourceFORcompanyinformationcontent1releasesmarket

MGI ANNOUNCES PARTNERSHIP WITH NEGEDIA: ENHANCE GENOMIC SEQUENCING TECHNOLOGIES AT THE SERVICE OF SCIENTIFIC RESEARCH AND PRECISION MEDICINE IN ITALY

In the study of rare diseases and precision medicine, understanding gene expression in the spatial context of tissues is essential. High-throughput sequencing and STOmics technology will...

Peer-Reviewed Study in Nature Scientific Reports Demonstrates Non-Invasive Fat Reduction Using Alma’s Energy-Based Technology

CAESAREA, Israel, June 27, 2025 /PRNewswire/ -- A newly published, peer-reviewed study in Nature Scientific Reports, part of the prestigious Nature Portfolio, presents compelling clinical...

Peer-Reviewed Study in Nature Scientific Reports Demonstrates Non-Invasive Fat Reduction Using Alma’s Energy-Based Technology

CAESAREA, Israel, June 27, 2025 /PRNewswire/ -- A newly published, peer-reviewed study in Nature Scientific Reports, part of the prestigious Nature Portfolio, presents compelling clinical...

2025 KIA TELLURIDE RANKS NUMBER ONE IN ITS SEGMENT IN J.D. POWER 2025 U.S. INITIAL QUALITY STUDY (IQS)

Kia's Award-Winning Three-Row SUV Earns Top Spot in Upper Midsize SUV Segment 2025 Telluride named the Upper Midsize SUV segment winner in the J.D. Power...

2025 KIA TELLURIDE RANKS NUMBER ONE IN ITS SEGMENT IN J.D. POWER 2025 U.S. INITIAL QUALITY STUDY (IQS)

Kia's Award-Winning Three-Row SUV Earns Top Spot in Upper Midsize SUV Segment 2025 Telluride named the Upper Midsize SUV segment winner in the J.D. Power...

PEPG Investors Have the Opportunity to Lead the PepGen Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss...

CHAMPION IRON ANNOUNCES UPSIZE AND PRICING OF US$500 MILLION SENIOR NOTES DUE 2032

MONTRÉAL, June 26, 2025 /CNW/ - SYDNEY, June 27, 2025 - Champion Iron Limited (TSX: CIA) (ASX: CIA) (OTCQX: CIAFF) ("Champion" or the "Company")...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell protein that transports bile acids into cells. AX-0810 is an investigational ADAR-mediated RNA editing oligonucleotide (EON) designed to selectively modulate NTCP function by reducing toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure, which are common in cholestatic diseases.

Ultima Genomics Selected to Support the World’s Largest Proteomics Studies to Date Led by Regeneron Genetics Center

FREMONT, Calif., June 26, 2025 /PRNewswire/ -- Ultima Genomics, a developer of an innovative new ultra-high throughput sequencing architecture, today announced that its UG 100 ™ sequencing platform...

Global Cancer Immunotherapy Market Projected to Reach $247 Billion by 2029, Driven by 11.4% CAGR

"Harnessing the Power of the Immune System: How Cancer Immunotherapy and Oncolytic Virology Are Reshaping the Future of Oncology in a Digitally Driven Era" BOSTON,...

Press release: Transparency Notification from Shareholders

Transparency Notification from Shareholders

VIZSLA SILVER CLOSES US$100M BOUGHT DEAL OFFERING

VANCOUVER, BC, June 26, 2025 /PRNewswire/ - Vizsla Silver Corp. (TSX: VZLA) (NYSE: VZLA) (Frankfurt: 0G3) ("Vizsla Silver" or the "Company") is pleased to announce...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStudy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers